(Breast Cancer) Is Keytruda + Chemotherapy Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- March 7, 2022
- Read time: 1 minute
On February 10, 2022, Peter Schmid and colleagues from Imperial College London published results from the MK-3475-522/KEYNOTE-522 Phase III clinical trial in The New England Journal of Medicine, evaluating the efficacy and safety of the anti-PD-1 antibody Keytruda plus chemotherapy as neoadjuvant therapy in previously untreated early triple-negative breast cancer patients.
The MK-3475-522/KEYNOTE-522 Phase III clinical trial was a double-blind trial. Previously untreated early triple-negative breast cancer patients (N=1,174) were randomized 2:1 after 4 cycles of Keytruda 200 mg plus chemotherapy as neoadjuvant therapy (3-week cycles) into two groups: the Keytruda group (Keytruda 200 mg plus chemotherapy for 4 cycles in 3-week cycles, N=784) and the placebo group (placebo plus chemotherapy for 4 cycles then chemotherapy alone for 4 cycles in 3-week cycles, N=390). Primary endpoints were pathological complete response rate and event-free survival.
At a median follow-up of 39.1 months, the primary endpoint 36-month event-free survival rate was 84.5% for the Keytruda group vs. 76.8% for the placebo group. The Keytruda group had a 37% reduction in event risk.
Regarding safety, adverse events confirmed during neoadjuvant chemotherapy were consistent with the existing safety profile; no new adverse events were identified.
Based on the MK-3475-522/KEYNOTE-522 trial results, Peter Schmid and colleagues concluded: In previously untreated early triple-negative breast cancer patients, the use of anti-PD-1 antibody Keytruda plus chemotherapy as neoadjuvant therapy followed by postoperative Keytruda plus chemotherapy significantly improved event-free survival.
Source: Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer (N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.)
- Clinical Trial Medications
- Immunotherapy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4